Research programme: small molecule therapeutics - Elorac

Drug Profile

Research programme: small molecule therapeutics - Elorac

Alternative Names: Small molecules Heprotect™

Latest Information Update: 03 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gideon Pharmaceuticals
  • Developer Elorac
  • Class
  • Mechanism of Action 14-alpha demethylase inhibitors; Cyclo-oxygenase 2 inhibitors; Retinoic acid receptor agonists; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation; Mycoses; Pain; Psoriasis

Most Recent Events

  • 19 Jan 2017 Preclinical trials in Inflammation in USA
  • 19 Jan 2017 USPTO Issues Patent To Elorac for treating chronic inflammatory diseases
  • 15 Apr 2016 Preclinical trials in Psoriasis, Mycoses, Pain, Psoriasis in USA (unspecified route) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top